New registry to see if freezing or burning kidney tumors works Long-Term
NCT ID NCT05210933
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This registry follows 750 patients with small kidney tumors who are not good candidates for surgery. They receive either cryotherapy (freezing) or radiofrequency ablation (heating) to destroy the tumor. Researchers will track survival, kidney function, and complications over time, and collect blood and urine samples for lab studies.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- cryotherapy and radiofrequency ablation
- What this could lead to
- If successful, this registry could confirm that ablation is a safe and effective option for controlling small kidney tumors in patients who cannot have surgery.
- What could go wrong
- This is an observational registry, not a controlled trial, so it cannot prove cause and effect. The study is currently suspended, and results may take years to emerge.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 750 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2022
- Expected to finish
-
Dec 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult Albertans with a diagnosis of kidney cancer
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults with prior kidney tumor diagnosis; * Willing to permit provincial agencies (e.g Alberta Health Services, Alberta Health, Netcare, Service Alberta) to disclose health-related information to study; * Canadian and Albertan residents; * Signed informed consent. Exclusion Criteria: * Unwilling to participate in the study; * Unavailable for standard clinical urological care or follow-up in Alberta
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Renal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Alberta
Edmonton, Alberta, Canada
-
University of Calgary
Calgary, Alberta, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can two drugs shrink kidney tumors and their vein clots before surgery?
- Blood test aims to catch Cancer's return earlier
- Smart blood pressure monitoring may shield kidneys during robotic surgery
- Can a new drug target Hard-to-Treat kidney and ovarian cancers?
- Personalized dosing could tame kidney cancer Drug's side effects
- A Pre-Surgery Tune-Up: could it help older adults recover faster?